Women make up nearly two-thirds of the people who suffer from Alzheimer’s in the United States. They account for almost 4 million of the more than 6 million patients aged 65 and over who live with Alzheimer’s in the country; they also have a one-in-five risk of developing the neurological condition at 65. Researchers from Alzheimer’s Research UK have now discovered that hormone replacement therapy (HRT) may be able to lower women’s risk of developing Alzheimer’s in their lifetimes.
Past studies have determined that a gene called APOE4 may increase an individual’s risk of Alzheimer’s disease. In this new observational study, scientists sought to determine if HRT meant to alleviate menopause symptoms can also decrease the risk of Alzheimer’s. They found that hormone replacement therapy had an association with larger brain volumes and better memory scores for patients who carried the APOE4 gene and were more likely to develop dementia.
However, the researchers noted that it was still too early to conclusively state that HRT could effectively reduce Alzheimer’s risk in women. Their research was an observational study rather than a clinical trial, and it did not follow up on the women it studied to see if they developed dementia later on.
However, the researchers still said that their findings were encouraging and pointed to the potential importance of HRT in addressing mental disorders such as Alzheimer’s. The researchers, led by Norwich Medical School professor Anne-Marrie Minihane and professor Craig Ritchie from the University of Edinburgh, highlighted that more work was needed to understand the connection between hormone replacement therapy and brain changes.
The scientists examined data from more than 1,000 women who took part in an initiative to prevent Alzheimer’s dementia. All the participants were older than 50 years of age, and they had not been diagnosed with dementia before joining the initiative.
The team of investigators studied the MRI scans detailing patient brain volumes and cognitive test results. According to University of East Anglia professor Dr. Rasha Saleh, the team’s findings suggest that HRT had some association with “better memory and larger brain volumes” in APOE4 gene carriers. Saleh also stated that if the effects of HRT on dementia risk were studied in a clinical trial, they would be equal to a “brain age that was several years younger.”
Speaking during an interview, Minihane added that the study was a “very nice finding” and that the next stage of research was to begin clinical trials.
Many novel Alzheimer’s treatment approaches are being considered, and companies such as India Globalization Capital Inc. (NYSE American: IGC) are focusing on how cannabinoids can be tapped in the fight against this degenerative disease.
NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://ibn.fm/IGC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
